Table 2.
Multivariate Risk Factor Analysis for NAFLD in Lean Subjects
| Variable | OR (95% CI) | p-value |
|---|---|---|
| Model 1 | ||
| Age (yr) | 1.023 (1.012–1.034) | <0.001 |
| Male sex | 2.482 (1.992–3.098) | <0.001 |
| SNPs (PNPLA3 (GG) or TM6SF2 (CT+TT)) | 1.870 (1.505–2.325) | <0.001 |
| Metabolic unhealthy status (CO or DM or MS) | 3.382 (2.450–4.670) | <0.001 |
| Model 2 | ||
| Age (yr) | 1.006 (0.994–1.018) | 0.346 |
| Male sex | 0.833 (0.634–1.095) | 0.189 |
| SNPs (PNPLA3 (GG) or TM6SF2 (CT+TT)) | 1.936 (1.535–2.443) | <0.001 |
| Systolic blood pressure (mm Hg) | 0.998 (0.989–1.008) | 0.702 |
| Waist circumference (cm) | 1.154 (1.123–1.186) | <0.001 |
| Fasting glucose (mg/dL) | 1.024 (1.015–1.032) | <0.001 |
| Triglyceride (mg/dL) | 1.008 (1.006–1.010) | <0.001 |
| HDL (mg/dL) | 0.981 (0.970–0.992) | 0.001 |
| Model 3 | ||
| Age (yr) | 1.018 (1.007–1.030) | 0.001 |
| Male sex | 2.202 (1.744–2.781) | <0.001 |
| SNPs (PNPLA3 (GG) or TM6SF2 (CT+TT)) | 1.867 (1.494–2.332) | <0.001 |
| High blood pressure (BP≥130/85 mm Hg) | 0.978 (0.749–1.278) | 0.873 |
| Central obesity (F≥85 cm, M≥90 cm) | 2.218 (0.871–5.650) | 0.095 |
| Impaired fasting glucose (≥100 mg/dL) | 2.116 (1.662–2.696) | <0.001 |
| High triglyceride (≥150 mg/dL) | 3.367 (2.420–4.683) | <0.001 |
| Low HDL (F<50 mg/dL, M<40 mg/dL) | 1.837 (1.409–2.394) | <0.001 |
When calculating the OR for NAFLD, logistic regression analysis was executed.
NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; CI, confidence interval; SNPs, single nucleotide polymorphisms; PNPLA3, patatin-like phospholipase domain containing 3; TM6SF2, transmembrane 6 superfamily 2; CO, central obesity; DM, diabetes mellitus, MS, metabolic syndrome; HDL, high-density lipoprotein; BP, blood pressure; F, female; M, male.